Abstract
A randomized, placebo-controlled, double-blind trial was conducted using subjects with a body mass index over 25 kg/m2 and under 30 kg/m2. Eighty subjects were randomly assigned to receive either a placebo or Ecklonia cava extract (Seapolynol, 360 mg/day) for 12 weeks. In response to Seapolynol consumption, the body fat was significantly reduced from the baseline value. In the abdominal obesity subgroup, Seapolynol group presented with a significant decrease in total adipose tissue area, percent body fat and fat/lean mass ratio and an increase in skeletal muscle index. The oxidized low-density lipoprotein levels and endogenous antioxidant enzyme activities were significantly affected by Seapolynol supplementation. In addition, Seapolynol supplementation significantly increased the mRNA expression of lipid oxidation-related genes and decreased the expression of lipid synthesis-related genes. Inflammatory markers were also reduced by Seapolynol supplementation. In conclusion, Seapolynol may exert beneficial effects on obesity and related metabolic disorders in overweight and obese individuals.
Original language | English |
---|---|
Pages (from-to) | 356-364 |
Number of pages | 9 |
Journal | Journal of Functional Foods |
Volume | 46 |
DOIs | |
State | Published - Jul 2018 |
Bibliographical note
Funding Information:The authors are grateful to the participants in this study. This work was supported by the Bio-synergy Research Project ( NRF2012M3A9C4048761 ), funded by the Ministry of Science, ICT, and Future Planning through the National Research Foundation.
Publisher Copyright:
© 2018 Elsevier Ltd
Keywords
- Ecklonia cava extract
- Inflammatory stress
- Obesity
- Oxidative stress
- Polyphenol